Development asset linked to Tillomed Laboratories in public FDA and regional records.
pharma · No medical condition. · No medical condition
Tillomed Laboratories
Laboratorios Tillomed Spain S.L.U
Tillomed Laboratories drug portfolio — 75 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Luton, GB HQ
1 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Luton, GB
- Employees
- 1
- Programs
- 51
- Drugs
- 75
- Patents
- 0
Tillomed Laboratories pipeline
Portfolio lens on 75 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tillomed Laboratories drug portfolio — 75 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
apixaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved.
-
canagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
edoxaban
Blood and blood forming organs (B01)US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.
- Mechanism
- Coagulation factor X inhibitor
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: NPC1-like intracellular cholesterol transporter 1.
- Target
- NPC1-like intracellular cholesterol transporter 1
- Mechanism
- Niemann-Pick C1-like protein 1 inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
levodopa
Nervous system (N04)US regulatory status: approved. Molecular target: D(3) dopamine receptor.
- Target
- D(3) dopamine receptor
- Mechanism
- Dopamine D3 receptor agonist
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
linagliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
memantine
Nervous system (N06)Nervous system (N06) compound in Tillomed Laboratories's portfolio. Mechanism: Glutamate [NMDA] receptor negative allosteric modulator.
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
metformin hydrochloride
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Mitochondrial complex I (NADH dehydrogenase).
- Target
- Mitochondrial complex I (NADH dehydrogenase)
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
mirabegron
Genito-urinary system and sex hormones (G04)US regulatory status: approved. Molecular target: Beta-3 adrenergic receptor.
- Target
- Beta-3 adrenergic receptor
- Mechanism
- Beta-3 adrenergic receptor agonist
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
omalizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Immunoglobulin heavy constant epsilon.
- Target
- Immunoglobulin heavy constant epsilon
- Mechanism
- Ig epsilon chain C region inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
rasagiline
Nervous system (N04)Nervous system (N04) compound in Tillomed Laboratories's portfolio. Mechanism: Monoamine oxidase B inhibitor.
- Mechanism
- Monoamine oxidase B inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
testosterone
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Tillomed Laboratories in public FDA and regional records. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Tillomed Laboratories in public FDA and regional records.
-
vortioxetine
Nervous system (N06)US regulatory status: approved. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist